Improving the Methods for the Economic Evaluation of Medical Devices
Open Access
- 31 January 2017
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 26 (S1) , 70-92
Abstract
Medical devices (MDs) have distinctive features, such as incremental innovation, dynamic pricing, the learning curve and organisational impact, that need to be considered when they are evaluated. This paper investigates how MDs have been assessed in practice, in order to identify methodological gaps that need to be addressed to improve the decision‐making process for their adoption.We used the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist supplemented by some additional categories to assess the quality of reporting and consideration of the distinctive features of MDs. Two case studies were considered: transcatheter aortic valve implantation (TAVI) representing an emerging technology and implantable cardioverter defibrillators (ICDs) representing a mature technology. Economic evaluation studies published as journal articles or within Health Technology Assessment reports were identified through a systematic literature review. A total of 19 studies on TAVI and 41 studies on ICDs were analysed. Learning curve was considered in only 16% of studies on TAVI. Incremental innovation was more frequently mentioned in the studies of ICDs, but its impact was considered in only 34% of the cases. Dynamic pricing was the most recognised feature but was empirically tested in less than half of studies of TAVI and only 32% of studies on ICDs. Finally, organisational impact was considered in only one study of ICDs and in almost all studies on TAVI, but none of them estimated its impact.By their very nature, most of the distinctive features of MDs cannot be fully assessed at market entry. However, their potential impact could be modelled, based on the experience with previous MDs, in order to make a preliminary recommendation. Then, well‐designed post‐market studies could help in reducing uncertainties and make policymakers more confident to achieve conclusive recommendations. © 2017 The Authors.Health Economicspublished by John Wiley & Sons, Ltd.Keywords
Funding Information
- Seventh Framework Programme (HEALTH-F3-2012-305694)
This publication has 78 references indexed in Scilit:
- Cost-effectiveness of transcatheter valvular interventions: economic challengesEuroIntervention, 2013
- The cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative riskHeart, 2013
- Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health systemInternational Journal of Cardiology, 2013
- Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findingsJournal of Medical Economics, 2013
- Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic StenosisJACC, 2012
- A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable populationBMJ Open, 2012
- Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Children With Dilated CardiomyopathyJournal of Cardiac Failure, 2010
- Impact of Age and Medical Comorbidity on the Effectiveness of Implantable Cardioverter-Defibrillators for Primary PreventionCirculation: Cardiovascular Quality and Outcomes, 2009
- Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy versus Drug Therapy for Patients at High Risk of Sudden Cardiac DeathPharmacoEconomics, 2002
- Evaluating and improving the cost-effectiveness of the implantable cardioverter—defibrillatorAmerican Heart Journal, 1995